1. Home
  2. ADEA vs PBLS Comparison

ADEA vs PBLS Comparison

Compare ADEA & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adeia Inc.

ADEA

Adeia Inc.

HOLD

Current Price

$27.81

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$35.86

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADEA
PBLS
Founded
1990
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.6B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
ADEA
PBLS
Price
$27.81
$35.86
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$31.00
N/A
AVG Volume (30 Days)
1.3M
405.2K
Earning Date
05-04-2026
N/A
Dividend Yield
0.65%
N/A
EPS Growth
73.68
N/A
EPS
0.35
N/A
Revenue
$443,386,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.63
N/A
P/E Ratio
$81.03
N/A
Revenue Growth
17.91
N/A
52 Week Low
$11.61
$25.56
52 Week High
$34.34
$36.82

Technical Indicators

Market Signals
Indicator
ADEA
PBLS
Relative Strength Index (RSI) 49.80 66.14
Support Level $26.57 $26.42
Resistance Level $34.02 N/A
Average True Range (ATR) 2.02 2.44
MACD 0.38 0.32
Stochastic Oscillator 52.77 86.81

Price Performance

Historical Comparison
ADEA
PBLS

About ADEA Adeia Inc.

Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: